-
Vertex’s MoDAS System Gains NMPA Approval for Movement Disorder Assessment
•
China-based Vertex has announced receiving medical device approval from the National Medical Products Administration (NMPA) for its MoDAS (Movement Dysfunction Assessment Software) system. This marks a significant milestone as MoDAS is the first-in-class AI-based movement dysfunction assessment software globally. MoDAS: AI-Powered Movement Disorder AssessmentMoDAS is an artificial intelligence/machine learning (AI/ML)-powered…
-
BeiGene Launches Mental Health Program for Cancer Patients
•
China-based biotech BeiGene (Nasdaq: BGNE; HKG: 6160; SHA: 688235) has announced the launch of a new mental health program focused on cancer patients. The “Talk About It: Cancer and Mental Health” program, which includes the website CancerandMentalHealth.com, is designed to ensure that mental health is considered a vital part of…
-
AnHeart Therapeutics Partners with Guardant Health for Taletrectinib Diagnostics
•
Sino-US biopharma AnHeart Therapeutics and US precision oncology firm Guardant Health Inc. (NASDAQ: GH) have unveiled a partnership under which Guardant will provide companion diagnostics in support of AnHeart’s taletrectinib. This collaboration aims to enhance the development, regulatory approval, and commercialization of Guardant360 CDx and Guardant360 TissueNext assays in the…
-
Grand Pharma’s TLX101 Accepted for NMPA Review for Glioblastoma Treatment
•
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that an Investigational New Drug (IND) filing for its TLX101, a radionuclide drug conjugate (RDC) being developed to treat glioblastoma multiforme, has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant step in the development…
-
Forlong Biotechnology Secures Series A Funding for Protein Drug Development
•
Forlong Biotechnology, a synthetic immunology-driven protein drug developer based in Suzhou, has reportedly raised upwards of RMB 100 million (USD 14.74 million) in a Series A financing round. This significant capital injection will support the company’s ongoing efforts in research and development (R&D), pipeline filing and clinical trials, and business…
-
Haisco Pharmaceutical Announces Public Offering for Clinical Studies
•
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) is set to make another public offering of 40 million shares, priced at RMB 20 (USD 2.95) per share, to the Shenzhen Stock Exchange. This move aims to raise significant capital for the company’s ongoing drug development initiatives. Use of ProceedsThe proceeds…
-
BDgene’s CRISPR-Cas9 Therapy BD111 Accepted for CDE Review
•
Shanghai BDgene Technology Co., Ltd has announced that a clinical trial filing for its BD111, a CRISPR-Cas9 in vivo-based therapy for herpes simplex virus (HSV)-related keratitis (HSK), has been accepted for review by the Center for Drug Evaluation (CDE). This marks a significant step forward in the development of innovative…
